Identification of Serum Biomarkers and Pathways of Systemic Lupus Erythematosus with Skin Involvement Through GC/MS-Based Metabolomics Analysis

References

• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi:10.1056/NEJMra1100359
   PubMed Web of Science ®Google Scholar
• Deng GM, Tsokos GC. Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol. 2015;11:663–669. doi:10.1038/nrrheum.2015.106
   PubMed Web of Science ®Google Scholar
• Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol. 1996;135(3):355–362. doi:10.1046/j.1365-2133.1996.d01-1004.x
   PubMed Web of Science ®Google Scholar
• Kuhn A, Wenzel J, Weyd H. Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. 2014;47(2):148–162. doi:10.1007/s12016-013-8403-x
   PubMed Web of Science ®Google Scholar
• Xie Y, Liu B, Wu Z. Increased interleukin-9 levels in skin lesion from cutaneous lupus erythematosus patients may predict the progression to systemic lupus erythematosus. J Dermatol Sci. 2021;101:78–80. doi:10.1016/j.jdermsci.2020.10.016
   PubMed Web of Science ®Google Scholar
• Deng GM, Liu L, Kyttaris VC, Tsokos GC. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J Immunol. 2010;184:7154–7161. doi:10.4049/jimmunol.0902514
   PubMed Web of Science ®Google Scholar
• Yu H, Jiang L, Liu R, et al. Association between the ratio of aryl hydrocarbon receptor (AhR) in Th17 cells to AhR in treg cells and SLE skin lesions. Int Immunopharmacol. 2019;69:257–262. doi:10.1016/j.intimp.2019.01.039
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li X, Yin X, et al. Metabolomic profiling reveals serum L-pyroglutamic acid as a potential diagnostic biomarker for systemic lupus erythematosus. Rheumatology. 2021;60:598–606. doi:10.1093/rheumatology/keaa126
   PubMed Web of Science ®Google Scholar
• Yan R, Jiang H, Gu S, et al. Fecal metabolites were altered, identified as biomarkers and correlated with disease activity in patients with systemic lupus erythematosus in a GC-MS-based metabolomics study. Front Immunol. 2020;11:2138. doi:10.3389/fimmu.2020.02138
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yin X, Wang H, et al. Fecal metabolomics and potential biomarkers for systemic lupus erythematosus. Front Immunol. 2019;10:976. doi:10.3389/fimmu.2019.00976
   PubMed Web of Science ®Google Scholar
• Kalantari S, Chashmniam S, Nafar M, Zakeri Z, Parvin M. Metabolomics approach reveals urine biomarkers and pathways associated with the pathogenesis of lupus nephritis. Iran J Basic Med Sci. 2019;22:1288–1295. doi:10.22038/ijbms.2019.38713.9178
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928
   PubMed Web of Science ®Google Scholar
• Hsu P-C, Lan RS, Brasky TM. Metabolomic profiles of current cigarette smokers. Mol Carcinog. 2017;56(2):594–606. doi:10.1002/mc.22519
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Li LS, Sun JL, Guan K, Wei JF. (1)H NMR-based metabolomic study of metabolic profiling for pollinosis. World Allergy Organ J. 2019;12:100005. doi:10.1016/j.waojou.2018.11.005
   PubMed Web of Science ®Google Scholar
• Yan B, Huang J, Zhang C, et al. Serum metabolomic profiling in patients with systemic lupus erythematosus by GC/MS. Mod Rheumatol. 2016;26:914–922. doi:10.3109/14397595.2016.1158895
   PubMed Web of Science ®Google Scholar
• Baldermann S, Homann T, Neugart S, et al. Selected plant metabolites involved in oxidation-reduction processes during bud dormancy and ontogenetic development in sweet cherry buds (Prunus avium L.). Molecules. 2018;23(5):1197. doi:10.3390/molecules23051197
   PubMed Web of Science ®Google Scholar
• Jeong YJ, Hong SW, Kim JH, et al. Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive naïve T cells into Th1 cells by increased IL-12 secretions. Cell Immunol. 2011;266:192–199. doi:10.1016/j.cellimm.2010.10.005
   PubMed Web of Science ®Google Scholar
• Kennes B, Dumont I, Brohee D, Hubert C, Neve P. Effect of vitamin C supplements on cell-mediated immunity in old people. Gerontology. 1983;29:305–310. doi:10.1159/000213131
   PubMed Web of Science ®Google Scholar
• Maeng HG, Lim H, Jeong YJ, et al. Vitamin C enters mouse T cells as dehydroascorbic acid in vitro and does not recapitulate in vivo vitamin C effects. Immunobiology. 2009;214:311–320. doi:10.1016/j.imbio.2008.09.003
   PubMed Web of Science ®Google Scholar
• Wintergerst ES, Maggini S, Hornig DH. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann Nutr Metab. 2006;50:85–94. doi:10.1159/000090495
   PubMed Web of Science ®Google Scholar
• Carneiro JR, Fuzii HT, Kayser C, et al. IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesion. Clinics. 2011;66:77–82. doi:10.1590/s1807-59322011000100014
   PubMed Web of Science ®Google Scholar
• Liu W, Liu XY, Qian YT, et al. Urinary metabolomic investigations in vitiligo patients. Sci Rep. 2020;10:17989. doi:10.1038/s41598-020-75135-0
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Silverberg NB. Serum homocysteine as a biomarker of vitiligo vulgaris severity: a pilot study. J Am Acad Dermatol. 2011;64:445–447. doi:10.1016/j.jaad.2010.08.025
   PubMed Web of Science ®Google Scholar
• Tsai TY, Kuo CY, Huang YC. Serum homocysteine, folate, and vitamin B (12) levels in patients with vitiligo and their potential roles as disease activity biomarkers: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:646–654.e645. doi:10.1016/j.jaad.2018.08.029
   PubMed Web of Science ®Google Scholar
• Lightfoot YL, Blanco LP, Kaplan MJ. Metabolic abnormalities and oxidative stress in lupus. Curr Opin Rheumatol. 2017;29:442–449. doi:10.1097/bor.0000000000000413
   PubMed Web of Science ®Google Scholar
• Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A. 2009;106(48):20423–20428. doi:10.1073/pnas.0910371106
   PubMed Web of Science ®Google Scholar
• Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73:326–334. doi:10.1016/j.cyto.2015.01.031
   PubMed Web of Science ®Google Scholar
• Gergely P Jr, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46(1):175–190. doi:10.1002/1529-0131(200201)46:1<175::AID-ART10015>3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Tumurkhuu G, Chen S, Montano EN, et al. Oxidative DNA damage accelerates skin inflammation in pristane-induced lupus model. Front Immunol. 2020;11:554725. doi:10.3389/fimmu.2020.554725
   PubMed Web of Science ®Google Scholar
• Li J, Ding H, Meng Y. Taurine metabolism aggravates the progression of lupus by promoting the function of plasmacytoid dendritic cells. Arthritis Rheumatol. 2020;72(12):2106–2117. doi:10.1002/art.41419
   PubMed Web of Science ®Google Scholar
• Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5(4):77–85. doi:10.1177/2042018814547204
   PubMedGoogle Scholar
• Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, Pilot Study in patients with systemic lupus erythematosus. J Clin Rheumatol. 1997;3(1):3–8. doi:10.1097/00124743-199702000-00002
   PubMedGoogle Scholar